Skip to main content
Quantum Genomics logo

Quantum Genomics — Investor Relations & Filings

Ticker · ALQGC ISIN · FR0011648971 LEI · 969500TFCD8K9RPM9K97 PA Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2020-07-07 Earnings Release
Country FR France
Listing PA ALQGC

About Quantum Genomics

https://quantum-genomics.com/

Quantum Genomics is a biopharmaceutical company focused on developing a new class of medications for cardiovascular diseases with high unmet medical needs, such as difficult-to-treat or resistant hypertension and heart failure. The company's core research is based on a breakthrough therapeutic approach involving the inhibition of Brain Aminopeptidase A (BAPA). Its lead drug candidate, firibastat, is a first-in-class BAPA inhibitor designed to offer a novel treatment mechanism for managing these conditions.

Recent filings

Filing Released Lang Actions
Bilan semestriel du contrat de liquidité contracté avec la Société de Bourse Gilbert Dupont
Earnings Release Classification · 99% confidence The document is titled "Bilan semestriel du contrat de liquidité contracté avec la Société de Bourse Gilbert Dupont" (Semi-annual balance sheet of the liquidity contract concluded with Gilbert Dupont Stock Brokerage Firm). It explicitly reports figures as of June 30, 2020, covering the activity during the "1er semestre 2020" (First half of 2020). This structure—a comprehensive report covering a period shorter than a full year (six months) and detailing financial/operational metrics—strongly indicates an Interim or Quarterly Report. While it specifically concerns a liquidity contract, the scope and timing align best with the definition of an Interim / Quarterly Report (IR). It is not a general Earnings Release (ER) as it provides detailed transaction tables, nor is it a full Annual Report (10-K). It is a specific report, not just an announcement of a report (RPA/RNS). H2 2020
2020-07-07 French
Quantum Genomics Appoints Benoît Gueugnon as Vice President of Finance
Board/Management Information Classification · 98% confidence The document is a press release announcing the appointment of a new Vice President of Finance, Benoît Gueugnon, and noting the departure of the previous incumbent. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The document length is short (3798 characters), but its content is a direct announcement, not a notice about an attached report, thus ruling out RPA/RNS based on the 'Menu vs Meal' rule contextually applied to the content type. Filing Code: MANG (Board/Management Information).
2020-01-28 English
Nomination de Benoît Gueugnon au poste de Vice-Président Finance
Board/Management Information Classification · 99% confidence The document is a press release announcing the appointment of Benoît Gueugnon as the new Vice-President of Finance, succeeding Marc Karako. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The document is short and structured like a formal corporate announcement, not a comprehensive financial report (like 10-K or IR) or a transcript.
2020-01-28 French
Quantum Genomics to Present at the Gordon Research Conference 2020 Dedicated to the Renin Angiotensin Aldosterone System
Regulatory Filings Classification · 95% confidence The document is a press release dated January 15, 2020, announcing that Quantum Genomics will present preclinical results at the Gordon Research Conference in February 2020. It also includes a financial calendar listing future events, such as the 'Publication of Financial Year 2019 Results' and 'Publication of Results for the 1st Half of 2020'. The core content is an announcement about participation in a scientific conference and future reporting dates, not the release of a full financial report (like 10-K or IR) or a transcript of a call. Since it is an announcement about company activities and future reporting schedules, it fits best under the general 'Regulatory Filings' (RNS) category as a corporate update that doesn't fit the more specific categories like ER, DIV, or CAP. It is not a Report Publication Announcement (RPA) because it is announcing a scientific presentation, not the publication of a formal financial report itself.
2020-01-15 English
Quantum Genomics fera une présentation à la Gordon Research Conference 2020 dédiée au Système Rénine Angiotensine Aldostérone
Regulatory Filings Classification · 90% confidence The document is a press release from Quantum Genomics announcing two main things: 1) A presentation of preclinical results at the Gordon Research Conference in February 2020, and 2) The company's financial calendar for 2020, which includes the release of 2019 results, the Annual General Meeting (AGM), and the H1 2020 results release. Since the document primarily announces future events, presentations, and a calendar, and does not contain the full content of an Annual Report (10-K), an Interim Report (IR), or the actual AGM materials, it fits best as a general announcement regarding corporate events and investor relations updates. Given the inclusion of the financial calendar and the announcement of the AGM date, it is related to investor communication. However, the core purpose is announcing participation in a scientific conference and providing a forward-looking calendar. This type of announcement, which is not a specific regulatory filing like 10-K, ER, or DIV, often falls under general regulatory announcements or investor relations updates. Since it announces the date of the AGM (June 25, 2020), it is highly relevant to shareholder meetings, but it is not the AGM presentation itself (AGM-R) or the proxy materials (PSI). It is a general update. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general press release detailing corporate events and schedules that doesn't fit a more specific category like ER or CT. It is not a Report Publication Announcement (RPA) because it is not announcing the publication of a specific report mentioned in the calendar (like the 2019 results), but rather announcing a conference presentation and the future calendar itself.
2020-01-15 French
Bilan semestriel du contrat de liquidité au 31 décembre 2019
Capital/Financing Update Classification · 99% confidence The document is titled "Bilan semestriel du contrat de liquidité au 31 décembre 2019" (Semi-annual statement of the liquidity contract as of December 31, 2019). It details the activity (purchases and sales of shares) under a liquidity contract managed by Gilbert Dupont for Quantum Genomics over the second half of the year. This type of report, detailing the status and activity of a share buyback/liquidity agreement, directly corresponds to the definition of 'Transaction in Own Shares' (POS), which covers share repurchase/issuance activities. Although it is a semi-annual report, the specific nature of the content (liquidity contract balance) makes POS a more precise fit than a general Interim Report (IR). The document is short and appears to be the report itself, not an announcement of a report, so RPA/RNS is less likely.
2020-01-06 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.